Latest research on Eprex

Human erythropoietin (recombinant), produced by CHO cells.

Latest findings

The in vitro cell proliferation assay (27) was performed using a TF-1 cell line in the presence of EPON24, N38, N83 2 or commercially available Epogin (recombinant human EPO). [source, 2016]
The concentrations of EPON24, N38, N83 2 and Epogin were varied from 10 pM to 100 nM. [source, 2016]
The synthesized EPON24, N38, N83 2 has biantennary sialyloligosaccharides, whereas Epogin has three sialyloligosaccharides in which the structure has a variety of bi- to tetraantennary forms. [source, 2016]
Because Epogin at 4.4 μM showed a saturation of hematopoietic activity, the data of Epogin at 1.4 μM were used for the comparison of synthetic EPO glycoforms 2 to 6. [source, 2016]
Among the synthesized EPO glycoforms, the most potent bioactive compound was found to be EPON24, N38, N83 2 (1.4 μM), although it displayed a lower hematopoietic activity than Epogin (1.4 μM) (day 2: 60%, day 5: 68%, day 7: 83% versus day 7 Epogin: 100%). [source, 2016]
If the three N-glycosylation positions of Epogin have three homogeneous tri- or tetraantennary sialyloligosaccharides, the activity of the hematocrit might be increased. [source, 2016]
Commercial lots of Erythropoietin (Procrit) IFNβ-1a (Avonex), and heparin were used. [source, 2015]
Before the development of Epogen, testosterone was used for renal failure patients with anemia. [source, 2015]
Patients were treated with the conventional treatment and Eprex. [source, 2015]
Following concerns for transmission of Creutzfeldt-Jacob disease, human serum albumin was removed from Eprex and replaced by polysorbate 80 and Glycine [3]. [source, 2015]